Hatice Bolek

13PUBLICATIONS
93CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 15, 2026
Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study.

|May 27, 2026
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis.

|Oct 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

Francesco Massari, Matteo Rosellini, Bohuslav Melichar

|Sep 27, 2025
Confirmation of Large Language Models in Head and Neck Cancer Staging.

Mehmet Kayaalp, Hatice Bölek, Hatime Arzu Yaşar

|Sep 13, 2025
FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG).

Ali Kalem, Tulay Kus, Taha Koray Sahin

|Aug 28, 2025
Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG).

Ali Kalem, Tulay Kus, Savas Gokcek

Pageof 3

Frequent Collaborators

6 joint publications

Yüksel Ürün

3 joint publications

Ali Kalem

3 joint publications

Mehmet Ali Nahit Sendur

2 joint publications

Taha Koray Sahin